FATE THERAPEUTICS INC — Director's Dealing 2020

Feb 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: FATE THERAPEUTICS INC (FATE)
CIK: 0001434316
Period of Report: 2020-01-30

Reporting Person: Wolchko J Scott (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-30	Common Stock	M	25000	$2.70	Acquired	444969	Direct
2020-01-30	Common Stock	S	25000	$25.4521	Disposed	419969	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-30	Stock Option (right to buy)	$2.70	M	25000	Disposed	2026-01-11	Common Stock (25000)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 19, 2019.

F2: Represents the weighted average sale price of the shares sold ranging from $25.06 to $25.95 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

F3: The shares subject to this option vested and became exercisable in 48 equal monthly installments beginning on January 1, 2016 such that this option was fully exercisable on December 1, 2019.

F4: Not applicable.